Johnson & Johnson Offered $2.1 Billion For LifeScan Diabetes Unit

Johnson & Johnson (J&J) recently announced it has been offered $2.1 billion for its LifeScan diabetes unit. The offer was made by Platinum Equity, a global firm specializing in mergers, acquisitions, and operations of companies that provide mission-critial products, services, and solutions.

With sales of its diabetes product companies falling over the past several years, J&J has previously stated it was exploring business options. The acceptance period for the offer on LifeScan—which generated about $1.5 billion in revenue during in 2017—is set to expire on June 15 of this year, with . . .